Acumen Prescribed drugs (NASDAQ:ABOS – Get Ranking) was downgraded by Zacks Financial investment Investigate from a “hold” rating to a “sell” ranking in a investigate be aware issued to investors on Tuesday, Zacks.com stories.
According to Zacks, “Acumen Pharmaceuticals Inc. is a scientific-phase biopharmaceutical company. It concerned in producing a novel ailment for Alzheimer. The company’s product pipeline consist ACU193. Acumen Prescription drugs Inc. is based mostly in CHARLOTTESVILLE, Va. “
Several other brokerages also not long ago issued stories on ABOS. Credit Suisse Group reduced their price goal on Acumen Prescription drugs from $26.00 to $17.00 and established an “outperform” rating on the inventory in a research report on Tuesday, March 29th. Lender of America elevated Acumen Pharmaceuticals from a “neutral” rating to a “buy” score and lowered their rate focus on for the company from $16.00 to $14.00 in a investigate report on Friday, January 21st. One particular analyst has rated the inventory with a sell score and 4 have issued a buy rating to the inventory. According to information from MarketBeat.com, Acumen Prescribed drugs at the moment has a consensus score of “Buy” and a consensus value focus on of $18.35.
Acumen Pharmaceuticals inventory traded up $.27 through mid-day buying and selling on Tuesday, hitting $3.58. 12,353 shares of the company’s stock were being exchanged, compared to its ordinary quantity of 243,723. Acumen Pharmaceuticals has a 1-yr very low of $3.25 and a 1-12 months higher of $26.98. The inventory has a 50 working day relocating average of $4.63 and a two-hundred day moving ordinary of $6.71.
A quantity of institutional investors and hedge funds have recently produced modifications to their positions in the business enterprise. Deutsche Lender AG obtained a new stake in shares of Acumen Prescription drugs throughout the 3rd quarter really worth somewhere around $82,000. Pura Vida Investments LLC acquired a new stake in shares of Acumen Prescription drugs in the 3rd quarter valued at close to $1,115,000. Goldman Sachs Group Inc. acquired a new stake in shares of Acumen Pharmaceuticals in the third quarter valued at around $946,000. BlackRock Inc. obtained a new stake in Acumen Pharmaceuticals through the 3rd quarter really worth $42,629,000. Eventually, BVF Inc. IL acquired a new position in shares of Acumen Prescribed drugs in the course of the 3rd quarter really worth $4,304,000. Hedge cash and other institutional buyers personal 64.42% of the company’s stock.
About Acumen Prescribed drugs (Get Score)
Acumen Prescription drugs, Inc, a clinical-phase biopharmaceutical firm, discovers and develops therapies for the procedure of Alzheimer’s ailment. The organization focuses on advancing a focused immunotherapy drug prospect ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to goal soluble amyloid-beta oligomers.
For far more details about study choices from Zacks Investment Study, visit Zacks.com
Want More Great Investing Strategies?
Get Information & Scores for Acumen Pharmaceuticals Each day – Enter your e-mail address below to receive a concise every day summary of the latest news and analysts’ scores for Acumen Prescription drugs and connected businesses with MarketBeat.com’s Free daily e-mail newsletter.